TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18769354
Drug: EVG/r (125/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVG/r (125/100 mg once daily)
Study: 12020337
Drug: 30 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/d of alcohol for 8 weeks
Study: 12020337
Drug: 15 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/d of alcohol for 8 weeks
Study: 12020337
Drug: 0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/d of alcohol for 8 weeks
Study: 10519499
Drug: Prerandomized consent
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prerandomized consent to experimental treatment
Study: 10519499
Drug: Prerandomized consent
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prerandomized consent to standard treatment
Study: 8537265
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g tds iv
Study: 8537265
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g tds iv
Study: 27916242
Drug: Pregabalin and
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin and methylcobalamin combination (PG‐B12)
Study: 23890528
Drug: Type I
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type I trimming technique (1-cm incision, glandular and subcutaneous tissue removal using scissors)
Study: 23013746
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) with 20 mg/kg alglucosidase alfa biweekly
Study: 20128370
Drug: Drug Eluting
Normalized name: Drug eluting stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Eluting Stent (DES)
Study: 17541390
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg (dose titrated to 300 mg if needed)
Study: 17541390
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg (dose titrated to 40 mg if needed)
Study: 9724486
Drug: Intensive diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive diabetes therapy aimed at near normoglycemia
Study: 7979840
Drug: Acarbose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (50 to 300 mg three times per day)
Study: 825076
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (TRH) stimulation
Study: 825076
Drug: Three intravenous
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three intravenous doses of 600 mug of TRH over 15 days
Study: 27791532
Drug: Rational emotive
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational emotive behaviour therapy (REBT)
Study: 25726502
Drug: Tenecteplase 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase 0.25 mg/kg (maximum 25 mg)
Study: 19807152
Drug: Xanthone-rich mangosteen
Normalized name: xanthine
DrugBank: Xanthine (DB02134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthone-rich mangosteen liquid (59 mL)
Study: 16731547
Drug: Norethisterone enanthate
Normalized name: norethindrone enanthate
DrugBank: Norethindrone enanthate (DB14678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone enanthate and testosterone undecanoate injections
Study: 10910852
Drug: IV verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV verapamil 2.5 mg and morphine 5 mg added to lidocaine solution (Group 3)
Study: 10910852
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine 5 mg and verapamil 2.5 mg added to lidocaine solution (Group 4)
Study: 10910852
Drug: verapamil 2.5
Normalized name: verapamil 2.5 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 2.5 mg and morphine 5 mg added to lidocaine solution (Group 5)
Study: 9071903
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (160 mg daily)
Study: 25882376
Drug: Thrombectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombectomy with stent retriever plus intravenous t-PA
Study: 25882376
Drug: Intravenous t-PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous t-PA alone (control group)
Study: 24195220
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (pinaverium bromide tablet)
Study: 15968385
Drug: LPS inhalation
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS inhalation
Study: 9203722
Drug: Monovalent type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent type 1 oral poliovirus vaccine (OPV) at 6 months and trivalent OPV at 7 and 9 months (Group 1)
Study: 9203722
Drug: OPV at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPV at birth and 3 doses of OPV and inactivated poliovirus vaccine (IPV) (Group 2)
Study: 9203722
Drug: Placebo at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at birth and 3 doses of IPV (Group 3)
Study: 9203722
Drug: Monovalent type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent type 1 OPV following 3 IPV doses (Group 2)
Study: 7703709
Drug: Orientation Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orientation Group intervention to reduce waiting time for treatment
Study: 3237852
Drug: Balloon inflated
Normalized name: LOBELIA INFLATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon inflated with 400 ml or more of water
Study: 31206595
Drug: Patch test
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch test reactivity to fragrance mix I
Study: 27052688
Drug: IV metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV metoprolol (15 mg bolus)
Study: 20100808
Drug: EQ plus
Normalized name: Anthelcide EQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: EQ plus 8 weeks of nicotine transdermal patch (EQ+)
Study: 15741547
Drug: Glucantime (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucantime (20 mg of antimony [Sb]/kg/day intravenously for 20 days)
Study: 15741547
Drug: Pentamidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentamidine (2 mg/kg every other day for seven injections)
Study: 9990361
Drug: Ointment base
Normalized name: Ointment base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment base (placebo)
Study: 7996960
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 200 ppb sulphur dioxide and 400 ppb nitrogen dioxide
Study: 29859917
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose lithium (150-600 mg) targeting a blood level of 0.2-0.6 mmol/L
Study: 27792869
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g transdermal testosterone gel (TT) daily for 12 months
Study: 27792869
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg anastrozole (AI) daily for 12 months
Study: 11809341
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 12 months
Study: 22457097
Drug: Extracorporeal cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal cardiac shock wave therapy (CSWT)
Study: 19583713
Drug: Itraconazole with
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole with lactobacilli (200 mg bid for acute infection followed by monthly single-day treatment)
Study: 19583713
Drug: Itraconazole without
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole without lactobacilli (200 mg bid for acute infection followed by monthly single-day treatment)
Study: 19583713
Drug: Classic homeopathy
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic homeopathy (CH) treatment for 12 months
Study: 9779696
Drug: CR oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR oxycodone every 12 hours
Study: 9779696
Drug: IR oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR oxycodone four times daily
Study: 3092656
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg three times daily and 400 mg at night
Study: 2735329
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g four times daily followed by 1 g twice daily after healing
Study: 25528496
Drug: Pilaralisib 600mg
Normalized name: Pilaralisib
DrugBank: Pilaralisib (DB11772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilaralisib 600mg capsules or 400mg tablets once daily
Study: 8576779
Drug: Risk factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk factor modification (cholesterol reduction therapy)
Study: 8576779
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists and diuretics
Study: 28806348
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 100 mg/day
Study: 28806348
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 300 mg/day
Study: 19080128
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with cisplatin and fluorouracil (PF) regimen
Study: 19080128
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (locoregional treatment alone)
Study: 16966497
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zolmitriptan nasal spray (ZNS5)
Study: 16966497
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zolmitriptan nasal spray (ZNS10)
Study: 16966497
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zolmitriptan nasal spray (ZNS5) (episodic cluster headache)
Study: 16966497
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zolmitriptan nasal spray (ZNS10) (episodic cluster headache)
Study: 16966497
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zolmitriptan nasal spray (ZNS5) (chronic cluster headache)
Study: 16966497
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zolmitriptan nasal spray (ZNS10) (chronic cluster headache)
Study: 3159401
Drug: Neuramide therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuramide therapy
Study: 21593041
Drug: Mipomersen (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen (dose not specified, up to 400 mg/week)
Study: 16945749
Drug: Aggressive medical
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive medical therapy
Study: 16945749
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention plus aggressive medical therapy
Study: 16945749
Drug: Sequential gSPECT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential gSPECT monitoring (n = 300)
Study: 9756286
Drug: Interventive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventive treatment (surgical ligation or angiographic embolization of the spermatic vein)
Study: 9756286
Drug: Counselling as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselling as the sole treatment
Study: 8165195
Drug: Superchar (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superchar (30 g)
Study: 8165195
Drug: Actidose (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actidose (30 g)
Study: 8165195
Drug: Charcoaid (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Charcoaid (30 g)
Study: 3349861
Drug: Cefoperazone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone (2 g i.v. every 8 h)
Study: 3349861
Drug: Chloramphenicol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol (500 mg orally every 6 h)
Study: 12531578
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (losartan 100 mg daily + trandolapril 3 mg daily)
Study: 12531578
Drug: Trandolapril alone
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trandolapril alone (3 mg daily)
Study: 12531578
Drug: Losartan alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan alone (100 mg daily)
Study: 10233213
Drug: Ticlopidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (300 mg daily for 6 days)
Study: 8729142
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acid capsules (9 g/d)
Study: 8729142
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (9 g/d)
Study: 30235716
Drug: Esketamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine (0.25 mg/kg)
Study: 28212067
Drug: PT+stimulant+risperidone (Augmented)
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PT+stimulant+risperidone (Augmented)
Study: 28212067
Drug: PT+stimulant+placebo (Basic)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT+stimulant+placebo (Basic)
Study: 22798186
Drug: Stapled or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stapled or sutured closure plus falciform ligament patch and fibrin glue (FF)
Study: 17622258
Drug: 343 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 343 microg [6S]‐5‐CH(3)H(4)PteGlu with 289.4 mg L‐AA
Study: 17622258
Drug: 343 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 343 microg [6S]‐5‐CH(3)H(4)PteGlu with 973.8 mg L‐AA
Study: 16929983
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow mononuclear cells transplanted by intracoronary infusion
Study: 16929983
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy alone (Control)
Study: 16929983
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow mononuclear cells
Study: 1653662
Drug: Beta-hydroxybutyrate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-hydroxybutyrate (3 mg min-1 kg-1 body weight)
Study: 6837082
Drug: Cold Air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold Air Inhalation Test (CAIT)
Study: 3768639
Drug: Domperidone 8
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 8 mg intravenously with standard barium sulphate preparation
Study: 3768639
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg intravenously with standard barium sulphate preparation
Study: 29420050
Drug: Mobile mindfulness
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile mindfulness meditation using the Headspace application for 30 days (10-20 minutes daily)
Study: 22689092
Drug: A +
Normalized name: Vital E- A + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: A + T (adjuvant anthracycline and taxane chemotherapy)
Study: 1867428
Drug: Nicardipine (1‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (1‐3 micrograms.kg‐1.min‐1, after a titration dose of 4.7 +/‐ 1.5 mg)
Study: 6297380
Drug: Topical enviroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical enviroxime nasal spray
Study: 30358417
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg daily for 1 month)
Study: 30358417
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (75 IU daily for 1 month)
Study: 25346896
Drug: Midazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (1 mg bolus and 0.1 mg/kg/hr, n=30)
Study: 25346896
Drug: Propofol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (20 mg bolus and 0.1 mg/kg/hr, n=30)
Study: 22052885
Drug: AmB (0.7-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmB (0.7-1 mg/kg) and 5-FC (25 mg/kg 4 times daily)
Study: 22052885
Drug: AmB (0.7-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmB (0.7-1 mg/kg) and fluconazole (800 mg daily)
Study: 22052885
Drug: AmB (0.7-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmB (0.7-1 mg/kg) and fluconazole (600 mg twice daily)
Study: 22052885
Drug: AmB (0.7-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmB (0.7-1 mg/kg) and voriconazole (300 mg twice daily)
Study: 11408002
Drug: Insulin-dependent diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetic patients with nephropathy
Study: 11408002
Drug: Insulin-dependent diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetic patients without nephropathy
Study: 11408002
Drug: Insulin-dependent diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetic patients with retinopathy
Study: 9439085
Drug: Naratriptan 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan 0.25 mg
Study: 9409334
Drug: Naratriptan 2.5
Normalized name: naratriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan 2.5 mg and 1 mg
Study: 8202976
Drug: Control (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (same physiotherapy and occupational therapy)
Study: 28432049
Drug: Swallowed aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Swallowed aspirin taken simultaneously with niacin
Study: 28432049
Drug: Orally dissolved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally dissolved aspirin taken simultaneously with niacin
Study: 28432049
Drug: Both orally
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both orally dissolved and swallowed aspirin taken simultaneously with niacin
Study: 20880286
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg bee pollen/kg BW
Study: 20880286
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg bee pollen/kg BW
Study: 20880286
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg bee pollen/kg BW
Study: 20880286
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg bee pollen/kg BW)
Study: 19660800
Drug: Zuidex (mid-urethral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuidex (mid-urethral injection)
Study: 19660800
Drug: Contigen (proximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contigen (proximal urethral cystoscopic injection)
Study: 14759446
Drug: HSD solution
Normalized name: HSD-016
DrugBank: HSD-016 (DB12419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSD solution (4 mL/kg during 20 minutes before cardiopulmonary bypass)
Study: 14759446
Drug: Ringer solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer solution (same volume as HSD)
Study: 11726445
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered using TCI at target concentrations of 1.5-4.5 microg/mL to pregnant women.
Study: 11726445
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered using TCI at target concentrations of 1.5-4.5 microg/mL to nonpregnant women.
Study: 3664551
Drug: Lotion (pyrethrin-piperonyl-butoxide)
Normalized name: Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion (pyrethrin-piperonyl-butoxide)
Study: 26424673
Drug: Ritonavir-boosted darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted darunavir 800 mg plus ritonavir 100 mg
Study: 22895370
Drug: 30G +
Normalized name: Insulin glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30G + MOD (30 g of glucose preexercise)
Study: 22895370
Drug: 0G +
Normalized name: Oxycodone and Gabapentin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0G + MOD (0 g of glucose preexercise)
Study: 22895370
Drug: 0G +
Normalized name: Oxycodone and Gabapentin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0G + MOD/INT (0 g of glucose preexercise with high-intensity intervals)
Study: 12872052
Drug: Hydrochlorothiazide (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (low-dose diuretic)
Study: 12872052
Drug: Candesartan (angiotensin-II-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (angiotensin-II-receptor blocker)
Study: 31851795
Drug: Anifrolumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anifrolumab (300 mg) every 4 weeks for 48 weeks
Study: 31234927
Drug: Pertuzumab plus
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab plus trastuzumab and chemotherapy (n=82)
Study: 31234927
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus trastuzumab and chemotherapy (control group; n=81)
Study: 27796604
Drug: Real tDCS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real tDCS plus occupational therapy
Study: 27796604
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS plus occupational therapy
Study: 19615959
Drug: Probiotic dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic dairy drink containing Lactobacillus casei DN-114 001 and yoghurt ferments (Actimel), consumed twice daily for 7 weeks (pilot) or 13 weeks (confirmatory).
Study: 19615959
Drug: Non-fermented control
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fermented control dairy product, consumed twice daily for 7 weeks (pilot) or 13 weeks (confirmatory).
Study: 12665918
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg once a day for one year